Second Chances in Arbitration – The German Federal Court of Justice Clarifies Conditions for Remittal to the Arbitral Tribunal

Key Takeaways

• Remittal not barred by every due‑process breach.
• Only grave, uncurable defects preclude tribunal reconsideration.
• Parties must plead remittal strategically in post‑award motions.
• Reconstituted tribunal may face new arbitrator challenges.
• Curability assessment crucial for efficient dispute resolution.

Summary

The German Federal Court of Justice (BGH) clarified that § 1059(4) ZPO permits remittal to the original arbitral tribunal unless a serious, uncurable procedural defect exists. The court rejected a blanket rule that any breach of the right to be heard bars remittal, limiting exclusion to obvious and grave violations that undermine tribunal integrity. In a life‑sciences M&A dispute, the BGH upheld a lower court’s decision to remit the case, finding the alleged hearing defect was not severe enough to preclude a renewed tribunal proceeding.

Pulse Analysis

The BGH’s decision marks a pivotal moment for German arbitration, refining the interplay between statutory remittal provisions and constitutional due‑process guarantees. By interpreting § 1059(4) ZPO as a flexible mechanism rather than an exception, the court affirms that procedural economy can be preserved even when an award is set aside, provided the underlying defect is remediable. This nuanced approach aligns German practice more closely with the UNCITRAL Model Law’s intent to keep disputes within the arbitral framework whenever feasible, reducing the likelihood of protracted court interventions.

For counsel, the judgment reshapes post‑award strategy. Lawyers must now evaluate early whether a procedural flaw is curable by the same tribunal and frame remittal requests with precision. Emphasizing the tribunal’s capacity to correct reasoning errors, burden‑of‑proof misapplications, or partial jurisdictional excesses can tip the balance toward remittal. Simultaneously, parties should anticipate that a reconstituted panel may trigger fresh challenges to arbitrator independence, potentially extending timelines and costs. Drafting clear remittal scopes mitigates the risk of the arbitration devolving into a quasi‑de novo proceeding.

The broader market impact is significant. By confirming that only severe, integrity‑threatening defects block remittal, the BGH encourages parties to favor arbitration continuity, preserving the confidentiality and expertise of specialized tribunals—especially in complex sectors like life sciences. This decision may spur revisions of arbitration clauses to explicitly invoke remittal rights, and it signals to international investors that German arbitration remains a predictable venue. Over time, the clarified standard could lead to fewer outright award set‑asides and a more efficient resolution landscape across Europe.